Allergan formally rejected the $46 billion unsolicited takeover bid made by Valeant Pharmaceuticals, saying the proposal substantially undervalues the botox maker.
WSJ.com: What's News US, Wall Street Journal
Mon, 05/12/2014 - 4:20am
Allergan formally rejected the $46 billion unsolicited takeover bid made by Valeant Pharmaceuticals, saying the proposal substantially undervalues the botox maker.